Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
4
×
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
biotech
boston
eli lilly
fda
indiana blog main
indiana top stories
rna interference
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
abbvie
acorda therapeutics
akcea therapeutics
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
amgen
ampyra
andrew fire
apokyn
apomorphine
arrowhead pharmaceuticals
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
craig mello
What
gets
4
×
drug
fda
approved
medicines
new
nod
rnai
abandoning
acorda
afternoon
ago
alnylam
alnylam’s
amgen
approval
baggage
candidates
class
companies
cope
cuts
deal
developed
development
dicerna
disease
episodes
free
friday
head
help
history
interference
landmark
late
long
looms
making
meant
Language
Current search:
gets
×
" boston top stories "
×
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines